Communicable Diseases

Evaluation of the District of Columbia's Demonstration Program,Managed Care System for Special Needs Children: Final Report

U.S. Department of Health and Human Services Evaluation of the District of Columbia's Demonstration Program, "Managed Care System for Disabled and Special Needs Children": Final Report

13 Indicators of Quality Child Care: Research Update

13 Indicators of Quality Child Care: Research Update Presented to: Office of the Assistant Secretary for Planning and Evaluation and Health Resources and Services Administration/Maternal and Child Health Bureau U.S. Department of Health and Human Services Presented by: Richard Fiene, Ph.D. Pennsylvania State University National Resource

Developing Quality Measures for Medicaid Beneficiaries with Schizophrenia: Final Report. 1. Measure Concepts Considered, Specified, and Tested, and Submitted for Endorsement

The project team sought to develop measures in three domains, pharmacology, psychosocial care, and physical health, as well as cross-cutting measures that span several of these domains. Tables III.1-III.4 list the proposed measure concepts, the measures that were specified and tested in focus groups, the measures that were tested in the MAX data,

G. Information Systems and Data Infrastructure

Strategies for Integrating and Coordinating Care for Behavioral Health Populations: Case Studies of Four States. G. Information Systems and Data Infrastructure

CCNC's work relies heavily on data and information systems at the program, network, and provider levels. At the program level, CCNC uses Medicaid claims data, real-time hospital data, and other clinical information from provider EHRs, along with proprietary risk-adjustment software developed by Treo Solutions, Inc., to identify "priority patients"

Strategies for Integrating and Coordinating Care for Behavioral Health Populations: Case Studies of Four States

This report describes the different strategies that four states--Louisiana, North Carolina, Tennessee and Vermont--are utilizing to improve the integration and coordination of care for individuals with mental health and substance use disorders. These strategies include introducing new managed care arrangements and care coordination mechanisms, enh

4CaseStud.pdf
PDF

Agency for Healthcare Research and Quality

Understanding the High Prevalence of Low-Prevalence Chronic Disease Combinations: Databases and Methods for Research. Agency for Healthcare Research and Quality Grouper System

Clinical Classifications System (CCS) Sponsorship: Agency for Healthcare Research & Quality Description:

Analysis of Integrated HIV Housing and Care Services. 1. River Region Human Services: Forging Useful Systems to Empower Project

Established in 1979 as a nonprofit behavioral health organization with mental health counseling, RRHS’s mission is to “improve the quality of life for individuals and families in northeast Florida affected by substance abuse, mental illness, homelessness, HIV/AIDS, and other communicable diseases through outreach, prevention, treatment, and ho

Examination of Clinical Trial Costs and Barriers for Drug Development. 2.1.2 Discussions with Experts, FDA Personnel, Drug Sponsors, Contract Research Organizations (CROs), and Academic Clinical Research Centers

Some of the information needed to characterize the decision process of a drug sponsor came from semi-structured discussions with our team of experts and other industry experts, FDA personnel, drug sponsors, CROs, and primary clinical research centers, including University of Massachusetts, Johns Hopkins University, University of Michigan, and the

Analytical Framework for Examining the Value of Antibacterial Products. A.6.2 Current Treatment

According to American Thoracic Society/Infectious Diseases Society of America guidelines, patients with no known risk factors for multi-drug resistant pathogens and early onset of disease may receive initial intravenous treatment with antibacterial drugs such as ceftriaxone, levofloxacin, moxifloxacin, ciprofloxacin, ampicillin/sulbactam, or ertap

Analytical Framework for Examining the Value of Antibacterial Products. 7 References

About NIAID . (2012, February 29). Retrieved November 12, 2012, from National Institute of Allergy and Infectious Diseases: http://www.niaid.nih.gov/about/pages/default.aspx Aldy, J. E., & Viscusi, W. K. (2008). Adjusting the Value of a Statistical Life for Age and Cohort Effects. The Review of Economics and Statistics, 90 (3), 573–581

Analytical Framework for Examining the Value of Antibacterial Products. 5.1.12 Expected Percentage Reduction in Revenues due to Increased Competition

The market for rapid POC diagnostics is competitive, especially for those infectious diseases that have the potential to impact sizeable populations, such as influenza and Group A Streptococcus . MRSA is one such market as there are many different strains of MRSA affecting a large number of individuals in many different healthcare settings at pre

Analytical Framework for Examining the Value of Antibacterial Products. 5.1.11 Market Uptake

Given the competitive landscape for rapid POC diagnostics for MRSA, we assume that the U.S. market share of the new entrant will range from 15 to 30 percent at peak-year sales with an expected market share of 24 percent given that the product launch success probability is estimated at 60 percent (= 60% × 30% + [(1 – 60%) × 15%) (see Section 3.

Analytical Framework for Examining the Value of Antibacterial Products. 5.1 Rapid POC Diagnostic Private ENPV Model Parameters and Assumptions

For the purposes of modeling the decision-making process and expected returns for a rapid point-of-care diagnostic producer, we selected a new rapid point-of-care diagnostic designed to identify methicillin-resistant Staphylococcus aureus (MRSA) that can cause serious infections, such as skin or wound infections, pneumonia, or infections of the bl

Analytical Framework for Examining the Value of Antibacterial Products. 5 Rapid Point-of-Care (POC) Diagnostics

There is a need for specific and inexpensive rapid point of care (POC) diagnostic tests that can be used for clinical management of infectious diseases. Diagnostics are important as they allow tailoring treatment with antibacterial drugs, reducing unnecessary antibacterial drug use and thereby delaying the development of antibacterial resistance

Analytical Framework for Examining the Value of Antibacterial Products. 4.2 Vaccine Private ENPV Model Parameters and Assumptions

For the purposes of modeling the decision-making process and expected returns for a vaccine producer, we chose to model a theoretical new vaccine effective in preventing acute bacterial otitis media (ABOM). ABOM was chosen because otitis media is an infectious disease for which efforts to develop a preventive vaccine are already underway; theref

Analytical Framework for Examining the Value of Antibacterial Products. 3.6.6.6 HABP/VABP

Total Number of Cases that Result in Death

Analytical Framework for Examining the Value of Antibacterial Products. 3.6.5.6 HABP/VABP

Total Number of Cases that do not Result in Death

Analytical Framework for Examining the Value of Antibacterial Products. 3.2.4 Pre-clinical, Clinical, and NDA/BLA Submission Phase Durations

Private ENPV is dependent on the duration of each phase and the distribution of out-of-pocket costs throughout each phase. Often times, there are overlaps as well as gaps among phases. For example, while Phase 1 may last for nearly 20 months, a company may initiate Phase 2 trials after having completed its single ascending dose tier studies wi

Analytical Framework for Examining the Value of Antibacterial Products. 2.1.4 Grants/Awards/Prizes for Antibacterial Product Research and Development

International-level support for research occurs primarily through public research institutions.

Analytical Framework for Examining the Value of Antibacterial Products. 2.1.3 Modifications to the Clinical Trial Process and Approval Standards

This incentive encompasses a number of ideas intended to streamline the clinical trial and drug approval processes for antibacterial drugs in order to shorten the timelines and, in turn, reduce the costs associated with developing these drugs. Easing the development requirements could reduce development costs by shortening the time to market for

Content by Keyword: Communicable Diseases